<DOC>
	<DOC>NCT01749462</DOC>
	<brief_summary>The purpose of the investigation is to confirm the ADR development and the contributing factors possibly having an impact on the safety under the post-marketing actual use of Oxis 9 mcg Turbuhaler.</brief_summary>
	<brief_title>Oxis 9mcg Turbuhaler Clinical Experience Investigation</brief_title>
	<detailed_description>Oxis 9mcg Turbuhaler Clinical Experience Investigation</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Patients treated with Oxis for the first time due to 'relief of various symptoms associated with airway obstructive disorders of chronic obstructive pulmonary disease (Chronic bronchitis, Pulmonary emphysema), which is the indication of this drug.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>chronic obstructive pulmonary disease,</keyword>
	<keyword>COPD,</keyword>
	<keyword>Oxis,</keyword>
</DOC>